Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Hederagenin inhibits proliferation, angiogenesis and inflammation of fibroblast-like synovial cells in rheumatoid arthritis

Ping Wang, Junli Yang, Xiaomeng Zhang

Department of Rheumatology, The Third Affiliated Hospital of Anhui Medical University, Hefei City, Anhui Province 230032, China;

For correspondence:- Xiaomeng Zhang Email: Z_xiaomeng6868@163.com Tel:+8655162189117

Accepted: 7 October 2023 Published: 30 October 2023

Citation: Wang P, Yang J, Zhang X. Hederagenin inhibits proliferation, angiogenesis and inflammation of fibroblast-like synovial cells in rheumatoid arthritis. Trop J Pharm Res 2023; 22(10):2047-2051 doi: 10.4314/tjpr.v22i10.4

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the effect of Hederagenin (Hed) on rheumatoid arthritis (RA) in a cell model, and to elucidate the mechanism of action of Hed.

Methods: MTT, EDU, and Immunoblot assays were used to determine the effects of Hed on the viability of fibroblast-like synovial cells, while the effects of Hed on inflammation were examined by enzyme-linked immunosorbent assay (ELISA) and immunoblot assay. The influence of Hed on cell motility angiogenesis was evaluated by Transwell and tube formation assays, while immunoblot analysis was used to determine the mechanism of action of Hed.

Results: Hed inhibited the viability of RA-FLS cells and suppressed the inflammation of RA-FLS cells (p < 0.05). Furthermore, Hed suppressed the migration and angiogenesis of RA-FLSl cells, as well as regulated MAPK pathway (p < 0.05).

Conclusion: Hed inhibits the proliferation, angiogenesis and inflammation of fibroblast-like synovial cells in RA by regulating MAPK pathway. Therefore, Hed is a drug for the treatment of RA, However, in vivo studies to validate these findings are recommended.

Keywords: Rheumatoid arthritis, Hederagenin, Inflammation, Angiogenesis, MAPK pathway